Cargando…
Systems and synthetic biology-driven engineering of live bacterial therapeutics
The past decade has seen growing interest in bacterial engineering for therapeutically relevant applications. While early efforts focused on repurposing genetically tractable model strains, such as Escherichia coli, engineering gut commensals is gaining traction owing to their innate capacity to sur...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10620806/ https://www.ncbi.nlm.nih.gov/pubmed/37929193 http://dx.doi.org/10.3389/fbioe.2023.1267378 |
_version_ | 1785130280814641152 |
---|---|
author | Kim, Kangsan Kang, Minjeong Cho, Byung-Kwan |
author_facet | Kim, Kangsan Kang, Minjeong Cho, Byung-Kwan |
author_sort | Kim, Kangsan |
collection | PubMed |
description | The past decade has seen growing interest in bacterial engineering for therapeutically relevant applications. While early efforts focused on repurposing genetically tractable model strains, such as Escherichia coli, engineering gut commensals is gaining traction owing to their innate capacity to survive and stably propagate in the intestine for an extended duration. Although limited genetic tractability has been a major roadblock, recent advances in systems and synthetic biology have unlocked our ability to effectively harness native gut commensals for therapeutic and diagnostic purposes, ranging from the rational design of synthetic microbial consortia to the construction of synthetic cells that execute “sense-and-respond” logic operations that allow real-time detection and therapeutic payload delivery in response to specific signals in the intestine. In this review, we outline the current progress and latest updates on microbial therapeutics, with particular emphasis on gut commensal engineering driven by synthetic biology and systems understanding of their molecular phenotypes. Finally, the challenges and prospects of engineering gut commensals for therapeutic applications are discussed. |
format | Online Article Text |
id | pubmed-10620806 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-106208062023-11-03 Systems and synthetic biology-driven engineering of live bacterial therapeutics Kim, Kangsan Kang, Minjeong Cho, Byung-Kwan Front Bioeng Biotechnol Bioengineering and Biotechnology The past decade has seen growing interest in bacterial engineering for therapeutically relevant applications. While early efforts focused on repurposing genetically tractable model strains, such as Escherichia coli, engineering gut commensals is gaining traction owing to their innate capacity to survive and stably propagate in the intestine for an extended duration. Although limited genetic tractability has been a major roadblock, recent advances in systems and synthetic biology have unlocked our ability to effectively harness native gut commensals for therapeutic and diagnostic purposes, ranging from the rational design of synthetic microbial consortia to the construction of synthetic cells that execute “sense-and-respond” logic operations that allow real-time detection and therapeutic payload delivery in response to specific signals in the intestine. In this review, we outline the current progress and latest updates on microbial therapeutics, with particular emphasis on gut commensal engineering driven by synthetic biology and systems understanding of their molecular phenotypes. Finally, the challenges and prospects of engineering gut commensals for therapeutic applications are discussed. Frontiers Media S.A. 2023-10-19 /pmc/articles/PMC10620806/ /pubmed/37929193 http://dx.doi.org/10.3389/fbioe.2023.1267378 Text en Copyright © 2023 Kim, Kang and Cho. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Bioengineering and Biotechnology Kim, Kangsan Kang, Minjeong Cho, Byung-Kwan Systems and synthetic biology-driven engineering of live bacterial therapeutics |
title | Systems and synthetic biology-driven engineering of live bacterial therapeutics |
title_full | Systems and synthetic biology-driven engineering of live bacterial therapeutics |
title_fullStr | Systems and synthetic biology-driven engineering of live bacterial therapeutics |
title_full_unstemmed | Systems and synthetic biology-driven engineering of live bacterial therapeutics |
title_short | Systems and synthetic biology-driven engineering of live bacterial therapeutics |
title_sort | systems and synthetic biology-driven engineering of live bacterial therapeutics |
topic | Bioengineering and Biotechnology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10620806/ https://www.ncbi.nlm.nih.gov/pubmed/37929193 http://dx.doi.org/10.3389/fbioe.2023.1267378 |
work_keys_str_mv | AT kimkangsan systemsandsyntheticbiologydrivenengineeringoflivebacterialtherapeutics AT kangminjeong systemsandsyntheticbiologydrivenengineeringoflivebacterialtherapeutics AT chobyungkwan systemsandsyntheticbiologydrivenengineeringoflivebacterialtherapeutics |